The board of directors of TOT BIOPHARM International Company Limited announced that Mr. Qiu, Yu Min has resigned from his roles as a non-executive director of the Company, the chairperson of the Remuneration Committee and a member of each of the Audit and Connected Transactions Review Committee and the Strategy and ESG Committee, all with effect from 12 August 2023, due to his other business engagements which require more of his dedication. Mr. Qiu will also resign from his position as a director of TOT BIOPHARM Co. Ltd., a wholly-owned subsidiary of the Company, in due course.

The Board announced that Dr. Liu, Weidong has been appointed as a non-executive director of the Company, the chairperson of the Remuneration Committee and a member of each of the Audit and Connected Transactions Review Committee and the Strategy and ESG Committee, all with effect from 12 August 2023. Dr. Liu, Weidong will also be appointed as a director of TOT Suzhou in due course. Dr. Liu, Weidong, aged 55, possesses extensive experience in pharmaceutical process research and development as well as CMC (chemistry, manufacturing and controls) management.

He obtained a bachelor's degree and a master's degree in chemistry from Peking University in China in 1989 and 1994, respectively, and obtained a Ph.D. in organic chemistry from the University of Pittsburgh in the United States in 2000. He worked at Array BioPharma Inc. from October 2001 to May 2015 with his last position as principal research investigator of process chemistry. He then worked at Avista Pharma Solutions from June 2015 to February 2016 as director of process chemistry, and at Changzhou STA Pharmaceutical R&D Co.

Ltd. a subsidiary of WuXi AppTec Co. Ltd. from March 2016 to April 2017 as executive director of process research and development. Dr. Liu, Weidong joined Vivo Capital LLC, a substantial shareholder of the Company, in August 2017 and is currently serving as managing director.

He served as a director of Genetron Holdings Limited between November 2019 and June 2021.